Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma

G. Santini, S. Nati, M. Spriano, A. Gallamini, D. Pierluigi, A. M. Congiu, M. Truini, A. Rubagotti, T. Chisesi, R. Vimercati, E. Rossi, M. R. Sertoli, D. Mattei, G. Marino, M. Gobbi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background and Objectives. We report the activity of two combinations of fludarabine (FLU), one with cyclophosphamide (FLU/CY) and the second with CY plus mitoxantrone (FLU/CY/MITO). The aim of the study was to evaluate the activity and toxicity of these two schedules in patients with non-Hodgkin's lymphoma (NHL). Design and Methods. Twenty-two patients with recurrent low grade non-Hodgkin's lymphoma (LGL) received FLU/CY (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3), and 31 patients received FLU/CY/MITO (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3, mitoxantrone 10 mg/m2 day 1). Patients received antibiotic oral prophylaxis during all treatments and growth factors (G-CSF) when grade III granulocytopenia (WHO scale) occurred. Results. Of the 53 patients, 31 achieved complete remission (CR) (58%) and 16 partial remission (PR) (30%). Response was similar in both arms of the study. After 3 courses, 77% of patients who achieved CR showed a complete disappearance of disease. Seventy-nine percent of patients experienced granulocytopenia. Few patients had fever, all without infection. One patient died with fever of unknown origin three months after completion of six courses of treatment. Interpretation and Conclusions. Both treatments were seen to be effective in recurrent low-grade NHL. Antibiotic prophylaxis with G-CSF support seems to reduce treatment-related infection.

Original languageEnglish
Pages (from-to)282-286
Number of pages5
JournalHaematologica
Volume86
Issue number3
Publication statusPublished - 2001

Fingerprint

Mitoxantrone
Non-Hodgkin's Lymphoma
Cyclophosphamide
Agranulocytosis
Antibiotic Prophylaxis
Granulocyte Colony-Stimulating Factor
Fever of Unknown Origin
fludarabine
Therapeutics
Infection
Intercellular Signaling Peptides and Proteins
Appointments and Schedules
Fever

Keywords

  • Cyclophosphamide
  • Fludarabine
  • Low-grade non-Hodgkin's lymphoma
  • Mitoxantrone

ASJC Scopus subject areas

  • Hematology

Cite this

Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. / Santini, G.; Nati, S.; Spriano, M.; Gallamini, A.; Pierluigi, D.; Congiu, A. M.; Truini, M.; Rubagotti, A.; Chisesi, T.; Vimercati, R.; Rossi, E.; Sertoli, M. R.; Mattei, D.; Marino, G.; Gobbi, M.

In: Haematologica, Vol. 86, No. 3, 2001, p. 282-286.

Research output: Contribution to journalArticle

Santini, G, Nati, S, Spriano, M, Gallamini, A, Pierluigi, D, Congiu, AM, Truini, M, Rubagotti, A, Chisesi, T, Vimercati, R, Rossi, E, Sertoli, MR, Mattei, D, Marino, G & Gobbi, M 2001, 'Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma', Haematologica, vol. 86, no. 3, pp. 282-286.
Santini, G. ; Nati, S. ; Spriano, M. ; Gallamini, A. ; Pierluigi, D. ; Congiu, A. M. ; Truini, M. ; Rubagotti, A. ; Chisesi, T. ; Vimercati, R. ; Rossi, E. ; Sertoli, M. R. ; Mattei, D. ; Marino, G. ; Gobbi, M. / Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. In: Haematologica. 2001 ; Vol. 86, No. 3. pp. 282-286.
@article{1c088cb163f9425f92fa0a6e587b9bea,
title = "Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma",
abstract = "Background and Objectives. We report the activity of two combinations of fludarabine (FLU), one with cyclophosphamide (FLU/CY) and the second with CY plus mitoxantrone (FLU/CY/MITO). The aim of the study was to evaluate the activity and toxicity of these two schedules in patients with non-Hodgkin's lymphoma (NHL). Design and Methods. Twenty-two patients with recurrent low grade non-Hodgkin's lymphoma (LGL) received FLU/CY (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3), and 31 patients received FLU/CY/MITO (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3, mitoxantrone 10 mg/m2 day 1). Patients received antibiotic oral prophylaxis during all treatments and growth factors (G-CSF) when grade III granulocytopenia (WHO scale) occurred. Results. Of the 53 patients, 31 achieved complete remission (CR) (58{\%}) and 16 partial remission (PR) (30{\%}). Response was similar in both arms of the study. After 3 courses, 77{\%} of patients who achieved CR showed a complete disappearance of disease. Seventy-nine percent of patients experienced granulocytopenia. Few patients had fever, all without infection. One patient died with fever of unknown origin three months after completion of six courses of treatment. Interpretation and Conclusions. Both treatments were seen to be effective in recurrent low-grade NHL. Antibiotic prophylaxis with G-CSF support seems to reduce treatment-related infection.",
keywords = "Cyclophosphamide, Fludarabine, Low-grade non-Hodgkin's lymphoma, Mitoxantrone",
author = "G. Santini and S. Nati and M. Spriano and A. Gallamini and D. Pierluigi and Congiu, {A. M.} and M. Truini and A. Rubagotti and T. Chisesi and R. Vimercati and E. Rossi and Sertoli, {M. R.} and D. Mattei and G. Marino and M. Gobbi",
year = "2001",
language = "English",
volume = "86",
pages = "282--286",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma

AU - Santini, G.

AU - Nati, S.

AU - Spriano, M.

AU - Gallamini, A.

AU - Pierluigi, D.

AU - Congiu, A. M.

AU - Truini, M.

AU - Rubagotti, A.

AU - Chisesi, T.

AU - Vimercati, R.

AU - Rossi, E.

AU - Sertoli, M. R.

AU - Mattei, D.

AU - Marino, G.

AU - Gobbi, M.

PY - 2001

Y1 - 2001

N2 - Background and Objectives. We report the activity of two combinations of fludarabine (FLU), one with cyclophosphamide (FLU/CY) and the second with CY plus mitoxantrone (FLU/CY/MITO). The aim of the study was to evaluate the activity and toxicity of these two schedules in patients with non-Hodgkin's lymphoma (NHL). Design and Methods. Twenty-two patients with recurrent low grade non-Hodgkin's lymphoma (LGL) received FLU/CY (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3), and 31 patients received FLU/CY/MITO (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3, mitoxantrone 10 mg/m2 day 1). Patients received antibiotic oral prophylaxis during all treatments and growth factors (G-CSF) when grade III granulocytopenia (WHO scale) occurred. Results. Of the 53 patients, 31 achieved complete remission (CR) (58%) and 16 partial remission (PR) (30%). Response was similar in both arms of the study. After 3 courses, 77% of patients who achieved CR showed a complete disappearance of disease. Seventy-nine percent of patients experienced granulocytopenia. Few patients had fever, all without infection. One patient died with fever of unknown origin three months after completion of six courses of treatment. Interpretation and Conclusions. Both treatments were seen to be effective in recurrent low-grade NHL. Antibiotic prophylaxis with G-CSF support seems to reduce treatment-related infection.

AB - Background and Objectives. We report the activity of two combinations of fludarabine (FLU), one with cyclophosphamide (FLU/CY) and the second with CY plus mitoxantrone (FLU/CY/MITO). The aim of the study was to evaluate the activity and toxicity of these two schedules in patients with non-Hodgkin's lymphoma (NHL). Design and Methods. Twenty-two patients with recurrent low grade non-Hodgkin's lymphoma (LGL) received FLU/CY (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3), and 31 patients received FLU/CY/MITO (FLU 25 mg/m2 days 1 to 3, CY 300 mg/m2 days 1 to 3, mitoxantrone 10 mg/m2 day 1). Patients received antibiotic oral prophylaxis during all treatments and growth factors (G-CSF) when grade III granulocytopenia (WHO scale) occurred. Results. Of the 53 patients, 31 achieved complete remission (CR) (58%) and 16 partial remission (PR) (30%). Response was similar in both arms of the study. After 3 courses, 77% of patients who achieved CR showed a complete disappearance of disease. Seventy-nine percent of patients experienced granulocytopenia. Few patients had fever, all without infection. One patient died with fever of unknown origin three months after completion of six courses of treatment. Interpretation and Conclusions. Both treatments were seen to be effective in recurrent low-grade NHL. Antibiotic prophylaxis with G-CSF support seems to reduce treatment-related infection.

KW - Cyclophosphamide

KW - Fludarabine

KW - Low-grade non-Hodgkin's lymphoma

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0035070261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035070261&partnerID=8YFLogxK

M3 - Article

C2 - 11255275

AN - SCOPUS:0035070261

VL - 86

SP - 282

EP - 286

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 3

ER -